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Abstract: 
The purpose of the present investigation was to increase the solubility and 
dissolution rate of rofecoxib by the preparation of its solid dispersion using 
Polyethylene glycol 6000 as a hydrophilic carrier in different proportion 
ranging from 1:2 to 1:12 using solvent evaporation method. Drug polymer 
interactions were investigated using Fourier transform infrared spectroscopy 
(FTIR). The solid dispersions prepared were subjected to assay, solubility 
and in vitro dissolution studies. The obtained results showed that the 
solubility was increased 5 fold over that of pure rofecoxib with 1:10 ratio of 
carrier and the dissolution rate considerably enhanced. The drug-to-carrier 
ratio was the controlling factor for dissolution improvement with maximum 
dissolution observed with 1:10 solid dispersion. This increase in the 
dissolution rate was due to improved wettability by the carrier. At higher 
level (after 1:10 ratio), the negative effect on dissolution appears that may be 
due to distortion of molecular dispersion structure, which leaves an insoluble 
drug particle and increased accumulation of carrier molecule in the bulk, to 
cause a saturation, by which further solubility of rofecoxib is retarded. FTIR 
spectra revealed no chemical incompatibility between the drug and PEG6000.  
The optimized 1:10 (RXB: PEG6000) solid dispersion was used in the 
formulation of tablet using microcrystalline cellulose as superdisintegant by 
direct compression. The Flowability and compressibility of the blend was 
found to be fair for compression. The tablet weight was maintained at nearly 
180mg. 
Keywords: Rofecoxib, Polyethylene glycol 6000, solid dispersions, FTIR, 
solvent method 
 
Introduction  
Rofecoxib (RXB) is a non-steroidal anti-inflammatory 
drug (NSAID), acting by inhibition of the synthesis of 
prostaglandins, by inhibiting the activity of the 
enzyme, cyclooxygenase-2 (COX-2) [1, 2]. It is 28,000 
times more selective for COX-2 than COX-1. 
Rofecoxib is practically insoluble in water, and peak 
blood level reaches between 2-3 h after oral 
administration [3, 4]. Dissolution is the rate-limiting 
step   in   the   process   of   drug  absorption.  Potential  
 
bioavailability problems are prevalent with extremely 
hydrophobic drugs (aqueous solubility less than 0.1 
mg/ml at 37°), due to erratic or incomplete absorption 
from GIT. The solid dispersion approach has been 
widely and successfully applied to improve the 
solubility, dissolution rates, and consequently, the 
bioavailability of poorly water-soluble drugs. A 
number of drugs have been shown to improve their 
dissolution character, when converted to solid 
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dispersions [5-8].  The present investigation was done 
as an attempt to improve solubility and dissolution of 
hydrophobic drugs through solid dispersions and 
formulate in to fast release tablets. Rofecoxib was used 
as model drug. The drug was withdrawn from the 
market in 2004 by Merck Inc as a result of its cardiac 
effects. 
 
Materials and methods 
Preparation of solid dispersions 
Solid dispersions containing Rofecoxib and carrier 
(PEG6000) in the proportion of 1:1, 1:2, 1:4, 1:6, 1:8, 
1:10 and 1:12 were prepared by  solvent evaporation 
method [9-11] using acetone as solvent. The solvent 
was removed at 45o c under vacuum. The solid residue 
was dried in a vacuum oven, passed through mesh no 
60 and stored in a well closed container.        
                
Drug content analysis 
An accurately weighed quantity of solid dispersion 
equivalent to 20 mg of RXB was taken into a 100 ml 
volumetric flask and dissolved in acetonitrile. Five ml 
of the filtrate was diluted to 100 ml with 0.1 N HCL, 
and assayed for drug content using a double beam 
UV/Vis spectrophotometer at 245 nm. 
  
Phase solubility study 
Solubility studies were performed according to the 
method described by Higuchi and Connors [12]. An 
excess amount of rofecoxib was placed into a 25-mL 
glass flask containing different concentrations of PEG 
6000 in 20 mL distilled water. All flasks were closed 
with stopper and covered with cellophane membrane to 
avoid solvent loss. The content of the suspension was 
equilibrated by shaking for 72 hours in a 
thermostatically controlled water bath at 25oC. After 
attainment of equilibrium, the content of each flask was 
then filtered. The filtrate was diluted and assayed 
spectrophotometrically (Schimadzu UV-110A Japan) 
for rofecoxib content at 245 nm. The solubility 
measurements were performed in triplicate.  
 
In vitro dissolution study 
The quantity of solid dispersions equivalent to 20 mg 
of RXB, was filled in colorless hard gelatin capsules by 
the hand filling method. Dissolution study of capsules 
was conducted using USP XXIII electrolab 8 basket tab 
dissolution test apparatus using paddle stirrer, in 900 
ml of 0.1 N HCL, maintained at 37±0.5° at a speed of 
50 rpm [13]. Five milliliters of samples were 
withdrawn at time intervals of 10, 20, 30, 45 and 60 
min. The volume of dissolution fluid was adjusted to 
900 ml, by replacing each 5 ml aliquot withdrawn with 
5 ml of 0.1 N HCL. The concentration of RXB in each 
sample was determined by using standard curve 
equation.  
 
Infra red spectroscopy 
IR spectra of RXB and solid dispersions were obtained 
by KBr pellet method using Perkin Elmer FTIR series 
model 1615 spectrometer in order to rule out drug 
carrier interaction occurring during the formulation 
process [14-18]. 
 
Preparation of RXB solid dispersion tablets  
All the ingredients shown in Table 1 were passed 
through mesh no 60, evaluated for flow properties, 
compressibility behavior and compressed on single 
punch machine with 8 mm flat faced punches. The 
percentage of each ingredient was optimized. The 
tablet weight was adjusted to approximately 180mg. 
 
Table 1: Optimized formulation of Rofecoxib solid 
dispersion tablets 
 
S. no Ingredients Percentage 
1 1: 10 RXB solid dispersion 
equivalent to 25 mg 
50 
2  Corn starch 20 
3 Micro crystalline cellulose 20 
4 Aspartame 0.5 
 
Evaluation of RXB solid dispersion tablets  
The tablets were evaluated for assay, hardness, 
friability, disintegration time and dissolution [19-20]. 
 
Hardness  
It is the tensile strength of tablets expressed in kg/cm2. 
It is the pressure required to break the tablet in to two 
halves by compression.  
 
Friability  
This test is performed to know the effect of friction and 
shocks on tablets. Preweighed sample of tablets was 
Sharma et al. International Journal of Drug Delivery 2 (2010) 32-36 
 
 34
placed in the friabilator (Roche friabilator), and 
operated for 100 revolutions. Tablets were dusted and 
reweighed. The test complies if tablets not loose more 
than 1% of their weigh.  
 
Assay  
Five tablets were crushed and from this, quantity 
equivalent to 20 mg of RXB was taken into a 100 ml 
volumetric flask and dissolved in acetonitrile. Five ml 
of the filtrate was diluted to 100 ml with 0.1 N HCL, 
and assayed for drug content using a double beam 
UV/Vis spectrophotometer at 245 nm.  
 
Disintegration time  
Disintegration time for tablets was determined using 
USP disintegration apparatus with 0.1 M HCl as the 
disintegrating medium. 
 
Dissolution test 
In vitro dissolution study on prepared tablets was 
performed in  0.1M HCL and Phosphate buffer (pH 
6.8)   using USP type II (paddle) apparatus operated at 
50 rpm (900 ml) for 60 minutes (37 ± 0.5°C).  
 
Results and discussion 
The percent drug content in all the dispersions 
contained 100±5% of the drug.  The solubility of 
rofecoxib in distilled water was found to 6mcg/ml 
(Figure 1).  
 
 
 
Figure 1. Solubility of  Rofecoxib in water at 25°C 
in the presence of PEG 6000. 
 
The obtained results showed that the solubility was 
increased 5 fold (31mcg/ml) over that of pure rofecoxib 
with 1:10 ratio of carrier.  It can be seen that from 
figure 2 that dissolution of rofecoxib increases with 
increases in PEG6000, up to 1:10 drug: PEG6000 ratio. 
The drug-to-carrier ratio was the controlling factor for 
dissolution improvement with maximum dissolution 
observed with 1:10 solid dispersion. This increase in 
the dissolution rate may be due to improved wettability 
by the carrier.  
 
 
Figure 2. Dissolution of rofecoxib from different 
solid dispersions in distilled water at 37°C. 
 
At higher level (after 1:10 ratio), the negative effect on 
dissolution appears. That may be due to distortion of 
molecular dispersion structure, which leaves an 
insoluble drug particle and increased accumulation of 
carrier molecule in the bulk, to cause a saturation, by 
which further solubility of rofecoxib is retarded. Figure 
3 shows the IR spectra of rofecoxib, PEG 6000, and 
their formulations.  
 
 
 
Figure 3: FTIR spectra of Rofecoxib-PEG 6000 
solid dispersions  
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Pure rofecoxib displays a peak characteristic of the C-
O bending vibration at 1150.5 cm−1 and a band with 
main strong peak at 1747.4 cm−1 indicative of the C=O 
stretch of the ester group. The spectrum of PEG6000 
showed important bands at 2955 cm−1 (C–H stretch) 
and1655 cm−1 (C=O). A very broad band was also 
visible at 3425 cm−1 that was attributed to the presence 
of water. The FTIR spectra of both physical mixture 
and solid dispersion still showed peak of the esteric 
C=O stretch vibration of the drug. Also a C-O vibration 
peak was still detected at the same position as that of 
drug. Consequently, the FTIR spectra of both physical 
mixture and solid dispersion seemed to be only a 
summation of drug and PEG6000 spectra. This result 
suggested that there was no interaction between drug 
and PEG6000 in their combinations. The table 2 shows 
the directly compressible blend has fair flow and 
compressible properties. The tablet mean hardness was 
found to be 2.7 kg/cm2. The tablets disintegrate within 
two minutes (78sec). The friability and assay was 
found 0.62% and 101.3%, respectively. The dissolution 
study was carried out in Purified water, 0.1 M HCL and 
phosphate buffer pH 6.8 figure 4, yielding about 42%, 
45% and 65% drug released respectively in 60 minutes. 
 
0
10
20
30
40
50
60
70
80
0 10 20 30 40 50 60 70
Time(minutes)
%
 R
XB
 d
is
so
lv
ed
0.1 HCL
PH. Buffer
Purified
water
Figure 4. Disolution of rofecoxib tablets (1: 10 solid 
dispersion) 
 
 
 
Table 2: Evaluation of optimized directly 
compressible blend and Tablets 
 
Angle of repose       37 
Bulk density ( gm/cm3)        0.52 
Tapped density  ( gm/cm3)   0.68 
% compressibility   23.52 
Flowability            Fair 
Hardness ( kg/cm2) 2.7 
Assay 101.3% 
Friability 0.62% 
Disintegration time 78 sec 
 
 
Conclusion 
The present study showed the suitability of PEG6000 
in ratio of 1:10 as a carrier for the preparation of 
rofecoxib fast release tablets via solid dispersion 
technique. 
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